Evidence map›Paper›PMID 40571969›Full record

ArticleFEBS open bio2025

Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor-adapted non-small cell lung cancer cell lines.

Tharsagini V Nanthaprakash, Campbell W Gourlay, Ina Oehme, Michelle D Garrett, Jindrich Cinatl, Mark N Wass, Martin Michaelis

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. A Darwinian Perspective on Tumor Evolution.International journal of biological sciences · 2026
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tharsagini V NanthaprakashSchool of Biosciences, Stacey Building, University of Kent, Canterbury, UK.ORCID https://orcid.org/0009-0005-5247-9484
Campbell W GourlaySchool of Biosciences, Stacey Building, University of Kent, Canterbury, UK.
Ina OehmeHopp Children's Cancer Center Heidelberg (KiTZ), Germany.ORCID https://orcid.org/0000-0002-0827-2356
Michelle D GarrettSchool of Biosciences, Stacey Building, University of Kent, Canterbury, UK.
Jindrich CinatlDr Petra Joh-Research Institute, Frankfurt am Main, Germany.
Mark N WassSchool of Biosciences, Stacey Building, University of Kent, Canterbury, UK.
Martin MichaelisSchool of Biosciences, Stacey Building, University of Kent, Canterbury, UK.ORCID https://orcid.org/0000-0002-5710-5888

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Here, we introduce novel sublines of the EGFR-mutant non-small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsProtein Kinase InhibitorsAntineoplastic AgentsCell Line, TumorCell PlasticityDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionErbB ReceptorsErlotinib HydrochlorideGefitinibHumansPhenotypeTyrosine Kinase InhibitorsAntineoplastic AgentsEGFR protein, humanErbB ReceptorsErlotinib HydrochlorideGefitinibProtein Kinase InhibitorsTyrosine Kinase Inhibitorsacquired drug resistancecell lineEGFREGFR tyrosine kinase inhibitornon‐small cell lung cancerplasticity

Identifiers

PMID40571969
PMCPMC12582973

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.